New Prostate Cancer Drug Pluvicto

SOURCE www.foxnews.com
Expanded approval for a new prostate cancer drug, Pluvicto, brings hope to patients with metastatic castration-resistant prostate cancer. The drug significantly reduces the risk of progression or death in clinical trials.

Key Points

  • Pluvicto is a targeted radioligand therapy given before chemotherapy
  • Expanded approval triples the number of eligible patients
  • Prostate cancer is the second leading cause of death among men

Pros

  • Significantly reduces the risk of progression or death in clinical trials
  • Targets PSMA-positive metastatic castration-resistant prostate cancer
  • Expands treatment options for patients

Cons

  • Adverse effects include dry mouth, fatigue, nausea, and constipation